AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03616886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
Study NCT03616886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
Study NCT03616886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
Study NCT03616886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
Study NCT01618955 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VIBEX MTX
Description: Self-administration of Single Dose of SC MTX using Vibex MTX 10 mg, 15 mg, 20 mg or 25 mg Device
Study NCT01804595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen
Study NCT01219075 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01219075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mammography
Description: Correlative studies
Study NCT01219075 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: mammography
Description: Correlative studies
Study NCT03724097 — intervention group
Intervention type: OTHER
Intervention: RNA sequencing
Description: Next Generation Sequencing of RNA from tumor samples, rRNA-depleted.
Study NCT03616886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
Study NCT03616886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI4736
Description: Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
Study NCT03616886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI9447
Description: Patients will be randomized between chemotherapy (paclitaxel and carboplatin) with immunotherapy including durvalumab with or without oleclumab (1:1 ratio).
Study NCT03724097 — intervention group
Intervention type: OTHER
Intervention: Transcriptome analysis
Description: Analysis of RNA-seq data using the Oncobox algorithm.
Study NCT01804595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-Message Reminders
Study NCT01804595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen and Text Message Reminders
Study NCT01993810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT01993810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT01804595 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Study NCT01804595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Study NCT03724097 — intervention group
Intervention type: DRUG
Intervention: target drug with the score above 0,1
Description: target drug with the score above 0,1
Study NCT01993810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT01993810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT01993810 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Given IV
Study NCT01993810 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT01993810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV
Study NCT01993810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT01769404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2605541
Study NCT01769404 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Study NCT03724097 — intervention group
Intervention type: DRUG
Intervention: target drug with the score equal or below 0,1
Description: target drug with the score equal or below 0,1
Study NCT03724097 — intervention group
Intervention type: DRUG
Intervention: non-target drug
Description: non-target drug
Study NCT03724097 — intervention group
Intervention type: DRUG
Intervention: palliative care
Description: palliative care
Study NCT03167398 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Patients able to swallow will be given capsulized FMT using 15 capsules a day for two consecutive days. Patients will be treated concomitantly with omeprazole 20mg once in the evening before FMT and daily for the next 2 days.
Study NCT02455323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suboccipital inhibitory
Description: According to this technique, the suboccipital musculature is palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure is applied, pushing the atlas anteriorly. The occiput rests on the hands while the atlas is supported by the fingertips. Finger pressure must be maintained for 10 minutes to produce the therapeutic effect of inhibiting the suboccipital soft tissues. The aim is to suppress spasm of the muscles and in general of the suboccipital soft tissues which are responsible for any dysfunctional mobility of the occiput, atlas, or even the axis.
Study NCT02455323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal manipulative
Description: This technique is performed along an imaginary vertical line passing through the odontoid process of the axis. No flexion or extension and very little lateroflexion are used. Application is bilateral. First, cephalic decompression is performed lightly, followed by small circumductions. Selective tension is applied to take up tissue slack and create a firm joint barrier. Manipulation is then performed with rotation towards the manipulated side in a helicoidal cranial movement. This technique is designed to correct a generalized dysfunction with the aim of restoring occiput, atlas, and axis joint mobility
Study NCT02455323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined treatment
Description: Consisted in applying the above two techniques using exactly the same sequence: first the SI technique, and then the SM technique.
Study NCT02455323 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group.
Description: The subjects received no treatment, but attended the same number of sessions, maintaining the resting position for longer than the experimental groups, and underwent the same evaluations (test for arterial compromise, and the three assessments).
Study NCT01783236 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Acetaminophen
Description: 1000mg IV Ofirmev given every six hours for a total of four doses.
Study NCT01783236 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Normal saline placebo given every six hours for a total of four doses if randomized to the placebo arm.
Study NCT01183637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kensey Nash Corp. Cartilage Repair Device
Description: To perform the Cartilage Repair Device implantation procedure, the surgeon first removes the damaged cartilage. Then, the surgeon creates a cylindrical hole in the bone below the area of damaged cartilage. The Cartilage Repair Device is then implanted into the hole so that the surface is level with the surrounding native cartilage. The Cartilage Repair Device will then absorb blood and bone marrow from the bone to begin the healing process.
Study NCT01183637 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: To perform the microfracture technique, the surgeon will first remove the damaged cartilage. Then, the surgeon will make a number of small fractures in the bone below the area of damaged cartilage. The fractures cause the bone to bleed and a clot to form over the exposed bone. Over time, the clot forms a layer of fibrocartilage over the bone.
Study NCT01269034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 1.25 mcg before the boost sub-cutaneously.
Study NCT01269034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapid and long acting insulin
Description: Depends on their Carbohydrate ratio and body needs
Study NCT01269034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: long acting insulin + rapid acting + 1.25 mcg Exenatide
Description: Depends on their body needs.
Study NCT01589094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Cisplatin (DD GC)
Description: Patients will receive six cycles of GC administered every 14 days. Gemcitabine 2,500 mg/m2 will be administered intravenously on day 1 and cisplatin 35 mg/m2 will be administered intravenously on days 1 and 2 of a 14 days cycle (with Peg GCSF). A total of six cycles of therapy will be administered followed by radical cystectomy with bilateral pelvic lymph node dissection (PLND)
Study NCT04411238 — intervention group
Intervention type: OTHER
Intervention: interview
Description: interview
Study NCT00609440 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: physiotherapeutic treatment
Description: At first, the patient was submitted to a conventional physiotherapeutic treatment and respiratory exercises; then, we gave emphasis to the motor development marks and to the march training; eventually, the kid was conducted to hydrotherapy.
Study NCT02988804 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endotracheal tube
Description: In the Endotracheal group In the ETT group, the procedure will be exactly the same except that the ETT will not be exchanged and the patient will be directly extubated~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~* baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~* end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~* at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment).
Study NCT02988804 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask
Description: In the LMA group, after aspirating pharyngeal secretions and with the patient still under general anesthesia, we will insert a Proseal LMA (Laryngeal Mask Co. Ltd., Le Rocher, Victoria, Mahe Seychelles) and extubate the trachea using a guided Bailey technique~Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:~* baseline, in the operating room before anesthetic induction (non invasive arterial pressure)~* end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)~* at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment).
Study NCT04170140 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Questionnaire
Study NCT00744367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: >1500 mg/day or maximum tolerated dose (MTD)
Study NCT00744367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: >1500 mg/day or maximum tolerated dose (MTD)
Study NCT00744367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pioglitazone
Description: >= 30 mg/day
Study NCT00744367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: >= 30 mg/day
Study NCT00744367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sc once weekly
Study NCT00744367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: taspoglutide
Description: 10 mg sc once weekly;
Study NCT00744367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 10 mg sc once weekly;
Study NCT00744367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: taspoglutide
Description: 20 mg sc once weekly (after 4 weeks of taspoglutide 10 mg sc once weekly)
Study NCT00744367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taspoglutide
Description: 20 mg sc once weekly (after 4 weeks of taspoglutide 10 mg sc once weekly)
Study NCT02330991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study NCT00479362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Warfarin is either interrupted or uninterrupted prior to device implantation
Study NCT00479362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin is either interrupted or uninterrupted prior to device implantation
Study NCT00479362 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Aspirin
Description: Aspirin is continued without interruption prior to device implantation
Study NCT00479362 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Permanent pacemaker
Description: Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
Study NCT00479362 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Permanent pacemaker
Description: Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
Study NCT00239980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dalteparin
Description: 50, 100, 150 IU/kg administered subcutaneously once daily for 3 cycles of chemotherapy
Study NCT02742246 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual clinician-provided CBT
Description: Individual clinician-provided CBT
Study NCT02742246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT4CBT
Description: CBT computer program assisted therapy
Study NCT00478140 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: For HER-2/neu positive biopsies, trastuzumab was administered intravenously, once every 3 weeks, at a loading first dose at 8 mg/kg over 90 minutes, and subsequent maintenance doses of 6 mg/kg over 90 minutes then every 30 minutes starting at the third dose.
Study NCT00478140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04551924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18034
Description: HR18034（Ropivacaine Liposome for Injection） is a sustained-release liposome
Study NCT04551924 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naropin
Description: Local infiltration of Naropin to produce anesthesia for surgery and analgesia in postoperative pain management. Naropin 150mg \[0.5%, 5mg/mL\] x 30mL
Study NCT03701100 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: tDCS
Study NCT02916082 — intervention group
Intervention type: PROCEDURE
Intervention: Cervical length measurement
Description: Vaginal ultrasound to measure cervical length previous to use of prostaglandins.
Study NCT01993810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT01993810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01993810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed Disodium
Description: Given IV
Study NCT01993810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV
Study NCT01993810 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon Beam Radiation Therapy
Description: Undergo photon beam radiation therapy
Study NCT01993810 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo proton beam radiation therapy
Study NCT01993810 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01993810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01993810 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01993810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03307343 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention will be delivered by trained research staff who are exercise physiologists or behavioral lifestyle counselors. This target reflects a recent expert statement concluding that desk-based workers should reduce workday sedentary behavior by 2-4 hr (by increasing standing and movement). The approach will combine: behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts. The initial in-person session will occur at the participant's office location. During months 2 and 3, one-on-one in-person meetings will occur at the research lab. Telephone intervention contacts will occur in the 3rd week of months 1-3.
Study NCT04081701 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ga68-DOTATATE-PET/MRI
Description: In patients with meningioma who are undergoing surgical planning, subjects will undergo a PET scan at the time of their pretreatment or preoperative standard of care MRI exam, prior to surgery performed for research purposes. Instead of the standard of care MRI exam, subjects will undergo a dedicated hybrid Gallium-68-DOTATATE PET/MRI.There will be up to two follow-up with Ga68-DOTATATE PET/MRI scans performed as standard of care.~In patients with SSTR-positive CNS tumors that are non-meningioma, MRI is often performed to assess extent of disease. Subjects may be asked to undergo a PET scan for research purposes at the time of their standard of care MRI. Instead of the standard of care MRI exam, they may be asked to undergo a dedicated hybrid Gallium-68-DOTATATE PET/MRI.
Study NCT01847495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 40mg/m2 x 3-5 days
Study NCT01847495 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife
Description: 45-60 Gy for 3-5 days CyberKnife SBRT to liver metastasis within 10 elapsed days. Irinotecan will be administered on the same day, prior to SBRT.
Study NCT03367702 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Description: Undergo IMRT
Study NCT03367702 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Undergo SBRT
Study NCT01189253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Study NCT01189253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trabectedin
Study NCT01189253 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Study NCT01189253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00479362 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Permanent pacemaker
Description: Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
Study NCT00479362 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Permanent pacemaker
Description: Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
Study NCT02812420 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT02812420 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo cystectomy with pelvic lymph node dissection
Study NCT02812420 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study NCT04293653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocol for patients above 75 undergoing emergency laparotomy or laparoscopy
Description: See above section
Study NCT01189253 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Study NCT00479362 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter-defibrillator
Description: Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
Study NCT00479362 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Cardioverter-defibrillator
Description: Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.